EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya

Rina Syarifah Salma, Made Putra Sedana, S. Ugroseno Yudho

Biomolecular and Health Science Journal · 2018

DOI: 10.20473/bhsj.v1i2.9244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecular and Health Science Journal, 2018. Verfasst von Rina Syarifah Salma und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non-Hodgkin Lymphoma (NHL) is a group of lymphoid-derived malignant disease with heterogenic biological and clinical manifestations. For over 30 years, CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) has been the first choice of chemotherapy for aggressive NHL. Later in 1997 Rituximab as anti-CD20 monoclonal antibody was introduced and then combined with CHOP as R-CHOP. The objective of this study is to acknowledge the response of the CHOP and R-CHOP therapy in Non-Hodgkin Lymphoma patients at Dr. Soetomo General Hospital.

Methods

The design of this study was retrospective observational study using secondary data obtained from patient’s medical records from 2011 to 2015. The data selected from the medical records are the result of the therapy, as well as patient’s gender and age.

Results

The results of patients’ therapy were classified into four categories: The study showed that 51.28% patients had Complete Response, followed by Partial Response (28.21%), Progressive Disease (17.95%), and No Change (2.56%). Sample characteristics showed male patients in higher percentage (66.67%), and the majority of patients’ age between 51-60 years old (30.77%). The use of CHOP and R-CHOP regiment were 76.92% and 20,52% respectively.

Conclusion

Most of the patients had a complete response. The CHOP regiment is more commonly used in patients compared to R-CHOP.

Zitieren

APA

Salma, R. S., Sedana, M. P., & Yudho, S. U. (2018). CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya. Biomolecular and Health Science Journal. https://doi.org/10.20473/bhsj.v1i2.9244

Vancouver

Salma RS, Sedana MP, Yudho SU. CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya. Biomolecular and Health Science Journal. 2018. doi:10.20473/bhsj.v1i2.9244

BibTeX
@article{Salma2018,
  author = {Salma, Rina Syarifah and Sedana, Made Putra and Yudho, S. Ugroseno},
  title = {CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya},
  journal = {Biomolecular and Health Science Journal},
  year = {2018},
  doi = {10.20473/bhsj.v1i2.9244}
}
Kostenlos starten →